Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | MLYCD | O95822 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | LCAT | P04180 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612209 | 0.83 | MAPT (0.65) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL17054917 | 0.82 | MAPT (0.68) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL18053948 | 0.81 | MAPT (0.70) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL21245532 | 0.81 | MAPT (0.62) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL31303379 | 0.81 | MAPT (0.62) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL17054792 | 0.80 | MAPT (0.68) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL23089248 | 0.80 | MAPT (0.60) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL18053939 | 0.79 | POLB (0.68) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL31607933 | 0.79 | POLB (0.68) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL25225534 | 0.79 | MAPT (0.59) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640247-B1 | SYK INHIBITOR AND USE METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-01-12 | — | — | EP | disclosed |
| US-11091460-B2 | Syk inhibitor and use method therefor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-08-17 | — | — | US | disclosed |
| CN-110678461-B | Syk inhibitors and methods of use thereof | 正大天晴药业集团股份有限公司 | 2021-08-10 | — | — | CN | disclosed |
| US-20200199101-A1 | SYK INHIBITOR AND USE METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-06-25 | — | — | US | disclosed |
| EP-3640247-A1 | SYK INHIBITOR AND USE METHOD THEREFOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-04-22 | — | — | EP | disclosed |
| CN-110678461-A | Syk inhibitors and methods of use thereof | 正大天晴药业集团股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091460-B2 | Syk inhibitor and use method therefor | SYK, BTK, LCK | MAPT 4018/4885POLB 3381/4885SMN1; SMN2 4795/4885 |
| US-20200199101-A1 | SYK INHIBITOR AND USE METHOD THEREFOR | SYK, BTK, LCK | MAPT 4018/4885POLB 3381/4885SMN1; SMN2 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.